Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Myelodysplastic Syndromes 1Leukemia 1Invasive Fungal Infections 1Hematologic Neoplasms 1Febrile Neutropenia 1

Interventions

Meropenem 3Ceftazidime 3Filgrastim 2Ciprofloxacin 2Cefepime 2ceftolozane, tazobactam drug combination 1Vancomycin 1Teicoplanin 1Simvastatin 1Positron Emission Tomography Computed Tomography 1Ofloxacin 1NF protocol 1Micafungin 1Metronidazole 1Levofloxacin 1Itraconazole 1Granulocyte Colony-Stimulating Factor 1Cilastatin, Imipenem Drug Combination 1Anti-Bacterial Agents 1Amikacin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Febrile Neutropenia × Micafungin × Other hematologic neoplasm × Clear all
NCT05784844 2024-09-19

Antimicrobial Revision in Persistent Febrile Neutropenia

Wake Forest University Health Sciences

Phase 4 Withdrawn
Classical hematologyLymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡